Principal Financial Group’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-19,796
| Closed | -$31.5K | – | 2512 |
|
|
2024
Q1 | $31.5K | Buy |
19,796
+775
| +4% | +$1.15K | ﹤0.01% | 2375 |
|
|
2023
Q4 | $16.3K | Sell |
19,021
-1,598
| -8% | -$1.4K | ﹤0.01% | 2391 |
|
|
2023
Q3 | $22.1K | Hold |
20,619
| – | – | ﹤0.01% | 2411 |
|
|
2023
Q2 | $53.4K | Buy |
20,619
+2,684
| +15% | +$9.57K | ﹤0.01% | 2356 |
|
|
2023
Q1 | $73.2K | Sell |
17,935
-768
| -4% | -$3.55K | ﹤0.01% | 2336 |
|
|
2022
Q4 | $93.9K | Buy |
18,703
+4,657
| +33% | +$29.2K | ﹤0.01% | 2300 |
|
|
2022
Q3 | $184K | Buy |
14,046
+856
| +6% | +$13K | ﹤0.01% | 2221 |
|
|
2022
Q2 | $169K | Buy |
+13,190
| New | +$183K | ﹤0.01% | 2321 |
|
|
2021
Q4 | – | Sell |
-14,628
| Closed | -$307K | – | 2668 |
|
|
2021
Q3 | $307K | Sell |
14,628
-2,371
| -14% | -$52.2K | ﹤0.01% | 2297 |
|
|
2021
Q2 | $335K | Buy |
16,999
+1,708
| +11% | +$40K | ﹤0.01% | 2325 |
|
|
2021
Q1 | $445K | Buy |
15,291
+1,077
| +8% | +$30.2K | ﹤0.01% | 2181 |
|
|
2020
Q4 | $431K | Sell |
14,214
-34,864
| -71% | -$763K | ﹤0.01% | 2149 |
|
|
2020
Q3 | $781K | Buy |
49,078
+16,159
| +49% | +$295K | ﹤0.01% | 1917 |
|
|
2020
Q2 | $650K | Buy |
+32,919
| New | +$629K | ﹤0.01% | 1910 |
|
Principal Financial Group's NGM Position: Q2 2024 in Review
Principal Financial Group sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 19,796 shares — an estimated $31.5K sold.
Principal Financial Group first reported a position in NGM in Q2 2020 and held it in 14 quarters. The position peaked at $781K in Q3 2020. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Principal Financial Group reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Principal Financial Group sold 19,796 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $31.5K.
- Principal Financial Group first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 14 quarters.
- Principal Financial Group's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $781K in Q3 2020.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Principal Financial Group's 13F filing for Q2 2024, filed 29 Jul 2024.